IPO Timeline
Broker Results (T-2)
2020-08-05
Some brokers release in afternoon
Grey Market (T-1)
2020-08-06
Afternoon
HKEX Allotment (T-1)
2020-08-06
Evening
Registrar Allotment (T-1)
2020-08-06
Evening
Listing Day (T)
2020-08-07
First day of trading
Cross-Market Price Comparison
| Other Listed Market | Shenzhen (SZSE) — 泰格医药 |
|---|---|
| Other Market Stock Code | 300347 |
| H-Share Offer Price | To be extracted |
| Other Market Price | Loading... |
| Reference Exchange Rate | Loading... |
| H-Share Offer Price Premium/Discount vs Other Market | Loading... |
Company Overview
| Stock Name | 杭州泰格醫藥科技股份有限公司 - Ｈ股 |
|---|---|
| Stock Code | 03347 |
| Company Full Name | 杭州泰格醫藥科技股份有限公司 - Ｈ股 |
| Industry | 醫療保健 |
| Principal Activities | 主要提供臨床試驗技術服務，以及臨床試驗相關服務及實驗室服務。 |
| Listing Date | 2020-08-07 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國浙江省杭州市濱江區江南大道618號東冠大廈15層 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | http://www.tigermedgrp.com |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | No data |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 100.00 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 0% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 2,301,900,000 |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | To be extracted |
| P/E Ratio | To be extracted |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
First Day Performance
| First Day Close | HK$ 113.3 |
|---|---|
| First Day Open | HK$ 119.0 |
| First Day Change | 13.30% |
| First Day Volume | 33927600.0 |
| First Day Turnover | 3926800000.0 |
Use of Proceeds
| Use of Proceeds | 1、15%或約1,540.9百萬港元用于內生擴大及提升我們在臨床試驗技術服務及臨床試驗相關服務種類及能力，以滿足海外市場對我們服務不斷增加的需求； 2、40%或約4,109.0百萬港元用于作為我們全球擴張計劃的一部分，為潛在收購可補足我們現有業務的具吸引力海外臨床合同研究機構提供資金； 3、20%或約2,054.5百萬港元用于內生通過對以創新業務模式營運及具增長潛力的公司進行少數股權投資，促進我們生物制藥研發生態系統發展； 4、10%或約1,027.3百萬港元用于償還我們截至2020年5月31日的若干未償還借款； 5、5%或約513.6百萬港元用于開發及推行技術以進一步提升我們綜合服務種類的質素及效率； 6、10%或約1,027.3百萬港元用于營運資金及一般企業用途。 |
|---|
Underwriting Syndicate
Joint Sponsors (4)
Merrill Lynch (Asia Pacific) Limited CE AAC198
海通国际资本有限公司 CE ADQ859
中信证券（香港）有限公司 CE AAK249
中国国际金融香港证券有限公司 CE AEN894
Overall Coordinators (6)
Merrill Lynch (Asia Pacific) Limited CE AAC198
海通国际证券有限公司 CE AAF806
中信里昂证券有限公司 CE AAB893
中国国际金融香港证券有限公司 CE AEN894
UBS Securities Hong Kong Limited CE BIN466
富瑞金融集团香港有限公司 CE ATS546
Joint Bookrunners (11)
Merrill Lynch (Asia Pacific) Limited CE AAC198
海通国际证券有限公司 CE AAF806
中信证券（香港）有限公司 CE AAK249
中国国际金融香港证券有限公司 CE AEN894
UBS Securities Hong Kong Limited CE BIN466
富瑞金融集团香港有限公司 CE ATS546
招银国际融资有限公司 CE AVM940
Credit Suisse (Hong Kong) Limited CE AAO017
复星国际证券有限公司 CE AAF432
工银国际证券有限公司 CE ARO299
东方证券（香港）有限公司 CE AVD362
Joint Lead Managers (4)
Merrill Lynch (Asia Pacific) Limited CE AAC198
海通国际证券有限公司 CE AAF806
中信证券（香港）有限公司 CE AAK249
中国国际金融香港证券有限公司 CE AEN894
Cornerstone Investors
This stock has no cornerstone investors.
Directors & Management
| Chairman | 葉小平 |
|---|---|
| Company Secretary | 翁美儀 |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 葉小平(20.32%);曹曉春(6.55%) |
|---|
IPO Timeline
